Article

Breast Cancer Patients Seek Improved Provider Communication over Financial Burden

Advancements in breast cancer treatment have improved survival rates, but financial hardships related to the cost of these lifesaving therapies can weigh heavily on patients.

Advancements in breast cancer treatment have improved survival rates, but financial hardships related to the cost of these lifesaving therapies can weigh heavily on patients.

Based on responses from a survey of 2500 patients treated for early-stage breast cancer and 845 treating surgeons, medical oncologists, and radiation oncologists, the authors identified an unmet need for clinician engagement regarding financial concerns after breast cancer diagnosis. The survey respondents were identified through population-based sampling from 2 Surveillance, Epidemiology, and End Results regions and their physicians.

Among the women diagnosed with breast cancer who were surveyed, 38% were at least somewhat worried about finances related to their treatment, and some experienced extensive hardships. Overall, 14% reported losing more than 10% of their household income and 17% spend more than 10% of their household income on out-of-pocket medical expenses. African-American and Latina women were more likely to report experiences with financial burden, including debt from treatment, losing their home, having utilities turned off for unpaid bills, and cutting back on spending for food.

Click to continue reading on Specialty Pharmacy Times.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com